Suppression of B-Raf(V600E) melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone

Most BRAF-mutated melanomas initially responsive to the FDA-approved inhibitors preferentially targeting B-Raf mutated in Val600 residue eventually relapse, requiring additional therapeutic modalities. Recent studies report the significance of metabolic reprograming in mitochondria for maintenance o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Biol Ther
Autori principali: Hong, Seung-Keun, Starenki, Dmytro, Wu, Pui-Kei, Park, Jong-In
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5362989/
https://ncbi.nlm.nih.gov/pubmed/27786591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2016.1250987
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi